AMG World’s Post

Last week, we shared insights on transformative strategies in pharmaceutical development. Join us on our next 4x4 Innovation Meet that is happening TODAY, 27 June 2024 at 22:00 (Singapore time). Attend here: https://lnkd.in/gd4apAEg #PharmaInnovation #DrugDevelopment #4x4InnovationMeet #Pharmaceuticals #HealthcareInnovation #BusinessStrategy #MarketStrategy

Want to know which Pharma companies are leading R&D budgets? 🧐 Check out the link below. 👀 What is the benefit of this for employees? 💥Increased pipeline & launch potential 💥Increased exposure promoting top quality products 💥Increased value add to HCP’s 💥Increased development opportunities 💥Increased postive patient outcomes 💥Increased reward & satisfaction in your role The list goes on…

At Vexella Pharmaceuticals, we’re not just envisioning the future of healthcare; we’re actively shaping it. Our mission is to blend innovation, science, and elegance to revolutionize the way we approach medicine and health. We’re excited to embark on a journey where cutting-edge technology meets compassionate care. Our forward-thinking vision is rooted in a commitment to: 🔬 **Innovate:** Harnessing the power of advanced research and technology to create groundbreaking pharmaceutical solutions. 🌐 **Transform:** Pioneering new treatments that address unmet medical needs and enhance quality of life. 💡 **Inspire:** Driving a culture of excellence and sophistication that sets new standards in the industry. Join us as we pave the way for a healthier tomorrow, one breakthrough at a time. Follow our page for updates on our latest advancements, research developments, and insights into the future of healthcare. Here’s to a future where innovation meets elegance—welcome to Vexella Pharmaceuticals! #Pharmaceuticals #Innovation #Healthcare #FutureOfMedicine #VexellaPharmaceuticals

Investment drives innovation, fosters economic growth, and propels us towards a brighter tomorrow. From life-saving medicines to groundbreaking technologies, R&D shapes our world for the better. Have a look at who is investing more into their R&D budgets. #ClinicalTrials #PharmaceuticalResearch #HPGConnect #ResearchAndDevelopment

Finding multiple use cases for your R&D investment plays a large role in de-risking your investment AND delivering a Return on Investment (ROI). Pharma, it turns out, has publicly available datasets that justify this conclusion. The data shows that thinking broadly about use case for a new compound is a critical component of an overall strategy for managing risk early in the investment phase. In pharma, early testing to find potential treatment indications for the compound gives you a number of 'shots on goal' as you look to spend over $1B to move your compound through clinical trials. When we investigated Roche, we saw that each New Molecule Entity (NME), as Roche defines them, had, on average, 7.5 indications and treatment modalities for each NME over our ten-year period. First, NME submissions for clinical trials were heavily biased towards oncology (see comment for our graph). When the first indication was not oncology, the majority of the time oncology was the second indication. This strategy outperforms others over the long run. Based on these observations, we can accurately predict Roche's next investments by knowing which phases of clinical trials it prefers. If you like insights like this, join us weekly at the 4x4 Innovation Group each Thursday @ 7AM Pacific where Martin Schweiger holds lively discussions with leading experts like Mike Rea on innovation strategies that ACTUALLY move the needle. Join us 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰 for the next 4x4 Innovation Meet to explore the latest developments across various industries: https://lnkd.in/gse8rcyA #innovationmanagement

Exploring Frontiers: Innovations and Insights in the Clinical Trials Market The Clinical Trials Market size was USD 58.4 Billion in 2022 and is anticipated to reach USD 86.4 Billion in 2032, growing at a rate of 4.0% from 2023 to 2032. A clinical trial is a research study that tests a new medical approach, device, medication, or other treatment. Clinical trials are used to determine whether new medical approaches are safe and effective. Clinical trials are conducted in phases. The first phase is designed to assess the safety of the new approach. The second phase is designed to assess its effectiveness. Key Players: The global clinical trails market includes players such as Pfizer, Clinipace, Novo Nordisk A/S, Eli Lilly and Company, Syneos Health, PRA Health Sciences, ICON Plc, Charles River Laboratory, Pharmaceutical Product Development , LLC, PAREXEL International Corporation, and IQVIA. In search of a comprehensive analysis and methodological overview of the report:  https://lnkd.in/dBKtd_BF #clinicaltrials #pharmaceuticalindustry #clinicaltrialsinnovation #clinicaltrialstechnology

💡 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰'𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 At our 4x4 Innovation Meet on June 20, 2024, industry leaders, including Mike Rea, CEO of IDEA Pharma, shared insights on transformative strategies in pharmaceutical development. 🔹𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐄𝐚𝐫𝐥𝐲-𝐏𝐡𝐚𝐬𝐞 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: A key discussion was the importance of implementing an appropriate market strategy from the start of drug development. Traditionally, early clinical trials focus on safety and efficacy. However, as Mike Rea showed with the Cymbalta case study, aligning these phases with market needs can increase commercial success and relevance. This makes market adoption smoother and more effective. 🔹𝐑𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐑&𝐃 𝐒𝐮𝐜𝐜𝐞𝐬𝐬 𝐌𝐞𝐭𝐫𝐢𝐜𝐬: We also examined the need to change how we measure R&D success. Instead of only aiming for regulatory approval, the industry should use metrics that predict long-term market success and impact on patients. This ensures that new medicines are not only approved, but also successful and beneficial to consumers. These discussions provide important guidance for the strategic positioning of new products in a competitive market. Join us 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰 for the next 4x4 Innovation Meet to explore the latest developments across various industries: https://lnkd.in/gse8rcyA #PharmaInnovation #DrugDevelopment #4x4InnovationMeet #Pharmaceuticals #HealthcareInnovation #BusinessStrategy #MarketStrategy Magnus Hakvåg, 🔑Maria Boicova-Wynants Donal O'Connell; Sanaz Javadi Farahzadi; Dr. Dominique Christ; Dr. Claas Gerding-Reimers; Erdem KAYA; Archana Pandit; Udo Gennari; Priggya Arora; Shalini Sitaraman Menezes; Magda Voltolini; Ivan Gauci; Mustafa Cakir, RTTP, QPIP, Bastian Best; Dr. Jörn Plettig; Martin Schlosser; Henry K.H. Wang; Philipp Hammans; David Perkins — Software Patent Expert; Mário Castro Marques; David Durand; David Kalow; Dr. Benjamin DELSOL (PhD, LL.M); Stefan Brehm; Bastian July; Ines Duhanic, LL.M. (Stockholm); Amr Eldakak; Matthew Wahlrab; Rich McDonnell; Bruce Vojak; Christian Behr; Sam Bergstrom

🌐 Inspiring Insights at "The Patient Pivot" Webinar by Impatient! Thrilled to have participated in the enlightening webinar. The session delved into the transformative power of patient partnerships in reshaping the landscape for pharmaceutical companies. 🔍 Key Takeaways: New Visions: Explored innovative perspectives on patient collaboration, unlocking fresh insights for the pharmaceutical industry. Team Restructuring: Discussed how patient partnerships can drive structural changes within teams, fostering a more patient-centric approach. Go-to-Market Strategies: Explored the art of reframing strategies to align with patient needs, ensuring a more impactful market presence. 🚀 Empowering Patient-Centric Approaches: The webinar emphasized the pivotal role patients play in steering the course of pharmaceutical initiatives. Their insights, experiences, and collaboration can truly redefine the way we approach healthcare. 🤝 Building Partnerships: The event shed light on the importance of fostering strong partnerships between pharmaceutical companies and patients. These collaborations can lead to groundbreaking advancements that prioritize patient well-being. 🌟 Thank you to Impatient Health for orchestrating such an insightful event! It's clear that the Patient Pivot is more than a concept; it's a catalyst for positive change in the pharmaceutical landscape. A heartfelt thank you for the esteemed panelists for sharing their invaluable insights. A special appreciation goes to Paul Simms for delivering an insightful and brilliant introduction, setting the stage for a thought-provoking conversation. 💬 Let's continue this vital conversation! Share your thoughts on patient partnerships and the future of pharmaceuticals in the comments below. #ThePatientPivot #PatientPartnerships #HealthcareInnovation #Pharmaceuticals #ImpatientWebinar

Traditional value measures, such as efficacy and safety, are no longer sufficient to convince payers to reimburse new medicines at a price that optimises access and supports commercial success. It is crucial to be prepared to respond to payers' evolving requirements. Adapting your evidence generation strategies to incorporate Real World Evidence, Patient Reported Outcomes, and other new data requirements will be vital to ensure the success of new innovative therapies. 💡 Download your copy of our latest white paper below to discover the key imperatives to achieve operational excellence in Value and Access and obtain a price that rewards innovation. https://lnkd.in/eSXQzC8e #Pharma #Pharmaceuticals #PharmaceuticalStrategy #Biopharma #Strategy #Consulting #OperationalExcellence #ValueandAccess #MarketAccess #Innovation #Pricing #ValueMeasures

Fierce Biotech have published their list of the top 10 pharma R&D budgets from 2023 which shows MSD leading investment in research, followed by Johnson & Johnson Innovative Medicine and Roche. You can find more information here https://lnkd.in/gGGbZgSX which includes more details behind the figures below: 1. MSD: R&D budget: $30.53 billion, Change from 2022: 126% 2. Johnson & Johnson Innovative Medicine: R&D budget: $15.1 billion, Change from 2022: 6.7% 3. Roche: R&D budget: 13.24 billion Swiss francs ($14.97 billion), Change from 2022: -5.7% 4. Novartis: R&D budget: $11.37 billion, Change from 2022: 23.9% 5. AstraZeneca: R&D budget: $10.94 billion, Change from 2022: 12% 6. Pfizer: R&D budget: $10.67 billion, Change from 2022: -6.65% 7. Eli Lilly and Company: R&D budget: $9.31 billion, Change from 2022: 29% 8. Bristol Myers Squibb: R&D budget: $9.29 billion, Change from 2022: -2.22% 9. AbbVie: R&D budget: $7.68 billion, Change from 2022: 18% 10. Sanofi: R&D budget: 6.73 billion euros ($7.32 billion), Change from 2022: 3% They have also included the data from S&P Capital IQ below highlighting the highest number of pipeline programs from 2023 which is interesting to contrast. #pharmaceuticalindustry #pharmaresearch #pharmaceuticalresearch #clinicaltrials #researchanddevelopment